TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05585983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxigrip Tetra Sanofi Pasteur Europe
Description: We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaxigrip Tetra Sanofi Pasteur Europe
Description: We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
Study: NCT06319677

Intervention type: DEVICE
Intervention: ECMO treatment
Description: Critically ill patients were treated with ECMO while receiving antimicrobial therapy
Study: NCT06220240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Training Programme
Description: Eccentric muscle contractions and 3-minute rest breaks will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Training Programme
Description: A routine training program will be used.
Study: NCT05111184

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education groupe
Description: Education
Study: NCT04989595

Intervention type: DEVICE
Intervention: MyIUS app
Description: Data will be self-reported by participants through the MyIUS app.
Study: NCT05604989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal Anti-VEGF injection
Description: Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: intravitreal Anti-VEGF injection
Description: Intravitreal anti-VEGF injection treatment in the neovascular AMD patients.
Study: NCT04799938

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 180 minutes of moderate-intensity exercise per week
Study: NCT04837924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia iliaca compartment block, (FICB) (levobupivacaine hydrochloride 0,25% 40 ml)
Description: Land mark technique will be used to perform FICB on the side of the hip fracture. The injection site is one centimetre caudal from the junction between medial 2/3 and lateral 1/3 in the imaginary line between anterior superior iliac spine and ipsilateral pubic tubercle. The goal is to administer local anesthetic in the fascia iliaca compartment.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: paracetamol 1 gram IV
Description: paracetamol 1 gram IV every six hours, 4 times in 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol 1 gram IV
Description: paracetamol 1 gram IV every six hours, 4 times in 24 hours

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rescue analgesic tramadol 100 mg IV if needed
Description: Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue analgesic tramadol 100 mg IV if needed
Description: Rescue analgesic, if needed, tramadol 100 mg in 100 ml saline (0,9% Sodium chloride) IV, up to 4 times in 24 hours

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sting with blunt needle, (without piercing the skin), same site as fascia iliaca compartment block
Study: NCT05742035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venipuncture
Description: Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Bloodletting of 450 mL, followed by separation of the whole blood in 2 blood components: 1 red blood cell concentrate and 1 plasma. Measurement of the outcomes in the red blood cell concentrate.
Study: NCT05753878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, PartA cohort 1
Description: A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, Part A cohort 2-7
Description: A single dose of HH-120 nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, Part A cohort 8-9
Description: Two doses of HH-120 nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 nasal spray, Part B
Description: HH-120 nasal spray, 10 times daily for 7 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray, Part B
Description: Placebo nasal spray, 10 times daily for 7 consecutive days.
Study: NCT06762314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide is long acting glucagon like peptide which is parenterally administered as subcutaneous injection once weekly with a half-life of about 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing the amount of glucose excreted in the urine
Study: NCT06761534

Intervention type: OTHER
Intervention: Screening of comprehensive geriatic assessment.
Description: The participants are screened before anti-tumor therapy with a comprehensive assessment screening tool developed for elderly cancer patients, which is more suitable for individualized decision-making in anti-tumor treatment.

Intervention type: OTHER
Intervention: the G8 assessment
Description: The G8 is a rapid geriatric screening test that takes only a few minutes to complete. It is used as a calibration standard to validate the novel screening tool in this study.

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: The participants screened as a high frailty risk will undergo CGA to determine the most appropriate treatment plan.
Study: NCT06760572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway insertion
Description: Tube will be inserted into the trachea to make airway data measurements.
Study: NCT06761300

Intervention type: OTHER
Intervention: Psychological assessment
Description: Psychological assessment evaluation at different time points and its correlation with pain outcomes and satisfaction with the SCS intervention.
Study: NCT05865405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MS CATCH
Description: Participants will respond to a set of surveys every month to increase communication on mood with their clinician.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MS CATCH
Description: Participants will respond to a set of surveys every month to increase communication on mood with their clinician.
Study: NCT05440006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib
Description: Fuzuloparib Capsules; 150mg; single dose per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib
Description: Fuzuloparib Capsules; 150mg; single dose per cycle.
Study: NCT04989595

Intervention type: DEVICE
Intervention: MyIUS app
Description: Data will be self-reported by participants through the MyIUS app.

Intervention type: DEVICE
Intervention: MyIUS app
Description: Data will be self-reported by participants through the MyIUS app.
Study: NCT04810845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Class II A device SmartCardia
Description: Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
Study: NCT06398431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walking analysis sensor
Description: Participant gait analysis with the inertial sensor
Study: NCT06184464

Intervention type: OTHER
Intervention: ACETATE LEUPRELINE
Description: USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
Study: NCT06279104

Intervention type: DRUG
Intervention: physician's choice of chemotherapy
Description: physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma

Intervention type: DRUG
Intervention: immune checkpoint inhibitor based therapy
Description: immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
Study: NCT05686226

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR-T cells
Description: Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Study: NCT06194955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIP(1-42)
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP(1-42)
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP(1-42)
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIP(1-42)
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLP-1
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLP-1
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-2
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLP-2
Description: Infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT04410224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN004
Description: ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
Study: NCT05637294

Intervention type: DEVICE
Group type: OTHER
Intervention: splinting
Description: neutral-positioned wrist orthosis

Intervention type: DEVICE
Group type: OTHER
Intervention: splinting
Description: neutral-positioned wrist orthosis

Intervention type: DEVICE
Group type: OTHER
Intervention: splinting
Description: neutral-positioned wrist orthosis
Study: NCT06488612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minced skin grafts for donor site
Description: After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage.
Study: NCT06420219

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04820257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based exercise
Description: Exercise at home and behavioural change to increase daily exercise
Study: NCT06453330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Horizontal platelet-rich fibrin (H-PRF)
Description: Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
Study: NCT05849441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aware Program
Description: The program includes interactive, multimedia lessons for adolescent participants to learn, practice, and apply different mindfulness skills. Parent-adolescent pairs will have the option to subscribe to a mobile messaging service that includes progress reminders, encouragement, and practice content. Parent participants also have access to online resources to support and monitor their teen's use of the program.
Study: NCT05431452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Nonpharmacological pain management during blood collection in preterm infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Nonpharmacological pain management during blood collection in preterm infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Nonpharmacological pain management during blood collection in preterm infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Nonpharmacological pain management during blood collection in preterm infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Nonpharmacological pain management during blood collection in preterm infants
Study: NCT05752201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gamma Variant RBD-based ARVAC-CG vaccine
Description: Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron Variant RBD-based ARVAC-CG vaccine
Description: Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent RBD-based ARVAC-CG vaccine
Description: Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Alum)
Description: Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Alum)
Description: Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Alum)
Description: Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
Study: NCT05885789

Intervention type: PROCEDURE
Intervention: Intubation in Bed-Up-Head-Elevated (BUHE) position
Description: Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
Study: NCT05641051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Cases will receive 10 mg intravenous metoclopramide every 6 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cases will receive the same volume of IV placebo / 6 hours.
Study: NCT06099678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic Band Training
Description: This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises.
Study: NCT05839340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Description: NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Description: NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assist Control Ventilation
Description: ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assist Control Ventilation
Description: ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
Study: NCT05618730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: punctum plug insertion
Description: EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eye Drops, Lubricant
Description: Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eye Drops, Lubricant
Description: Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
Study: NCT06099678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic Band Training with Maximal Mental Effort
Description: This training intervention will be 6 weeks of moderate-intensity elastic band training, including whole-body and isolated muscle exercises, where participants will perform maximal mental effort by imagining maximal muscle contraction during each exercise.
Study: NCT04882267

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team and Technology
Description: Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team and Technology
Description: Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
Study: NCT06241001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric streching
Description: The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM
Description: Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
Study: NCT05496686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.7 microCi 225Ac-MTI-201
Description: 4.7 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9.5 microCi of 225Ac-MTI-201
Description: 9.5 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 19 microCi of 225Ac-MTI-201
Description: 19 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38 microCi of 225Ac-MTI-201
Description: 38 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 76 microCi of 225Ac-MTI-201
Description: 76 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 152 microCi of 225Ac-MTI-201
Description: 152 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 254 microCi of 225Ac-MTI-201
Description: 254 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 424 microCi of 225Ac-MTI-201
Description: 424 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 564 microCi of 225Ac-MTI-201
Description: 564 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 microCi of 225Ac-MTI-201
Description: 750 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 998 microCi of 225Ac-MTI-201
Description: 998 microCi intravenous solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1327 microCi of 225Ac-MTI-201
Description: 1327 microCi intravenous solution
Study: NCT05826730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric Exercises
Description: Eccentric Exercises for neck muscles.
Study: NCT06237920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.